Darlene Dobkowski, Managing Editor for CURE® magazine, has been with the team since October 2020 and has covered health care in other specialties before joining MJH Life Sciences. She graduated from Emerson College with a Master’s degree in print and multimedia journalism. In her free time, she enjoys buying stuff she doesn’t need from flea markets, taking her dog everywhere and scoffing at decaf.
Augtyro ‘Fills a Gap’ in the Treatment of ROS1-Positive NSCLC
December 4th 2023The recent FDA approval of the next-generation tyrosine kinase inhibitor Augtyro provides patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer another treatment option when the disease becomes resistant to other therapies.
Adding a Novel Agent to Standard of Care May Improve Survival in Liver Cancer
October 13th 2023Adding TPST-1120 to the standard of care for the treatment of unresectable or metastatic hepatocellular carcinoma, a type of liver cancer, improved progression-free survival and overall survival in a phase 1b/2 clinical study.
‘The Complete Guide to Breast Reconstruction’ Author Empowers Patients With Information
October 5th 2023Now in its fifth edition, “The Complete Guide to Breast Reconstruction: Choosing the Best Options After Your Mastectomy” by two-time breast cancer survivor Kathy Steligo offers patients comprehensive, up-to-date information.
FDA Approval of Elrexfio Represents ‘a Very Hopeful Time’ for Heavily Pretreated Multiple Myeloma
August 28th 2023Elrexfio has been shown to provide patients with relapsed/refractory multiple myeloma who previously received four or more lines of therapy with a response that may last at least 15 months, an expert explained.